激活素A(ACVA)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Activin A (ACVA)
ACV-A; Activin Beta A Beta A Homodimer
- 編號(hào)UCEA001Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法競(jìng)爭(zhēng)抑制
- 反應(yīng)時(shí)長(zhǎng)2h
- 檢測(cè)范圍12.35-1,000pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于4.99pg/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 1323 ¥ 1890 ¥ 8505 ¥ 16065 ¥ 132300
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)激活素A(ACVA)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的激活素A(ACVA)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 88-102 | 92 |
| EDTA plasma(n=5) | 78-99 | 88 |
| heparin plasma(n=5) | 86-93 | 89 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的激活素A(ACVA)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中激活素A(ACVA)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 88-99% | 80-103% | 95-103% | 97-104% |
| EDTA plasma(n=5) | 83-96% | 85-92% | 84-101% | 98-105% |
| heparin plasma(n=5) | 97-105% | 89-98% | 90-97% | 96-103% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）50µL，
加入50µL檢測(cè)液A(臨用前配制);
37°C溫育1小時(shí)。
3. 洗板3次；
4. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
5. 洗板5次；
6. 加TMB底物90µL，37°C孵育10-20分鐘；
7. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
本試劑盒應(yīng)用競(jìng)爭(zhēng)抑制酶聯(lián)免疫分析法測(cè)定標(biāo)本中待測(cè)物質(zhì)水平。將激活素A(ACVA)單克隆抗體包被微孔板，制成固相載體，往包被抗體的微孔中同時(shí)加入生物素標(biāo)記的抗原和待測(cè)抗原(標(biāo)準(zhǔn)品或樣本)，待測(cè)抗原與生物素標(biāo)記抗原對(duì)特異性抗體進(jìn)行競(jìng)爭(zhēng)結(jié)合。溫育后經(jīng)洗滌去掉未結(jié)合物，然后加入HRP標(biāo)記的親和素，經(jīng)過(guò)溫育和徹底洗滌后加入底物TMB顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。待測(cè)標(biāo)本濃度越高，標(biāo)記抗原和抗體的結(jié)合就越受到抑制，顯色愈淺。顯色的深淺與酶量呈正相關(guān)，而與樣品中待測(cè)物質(zhì)含量呈負(fù)相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度（O.D.值），計(jì)算樣品濃度。
贈(zèng)品
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA001Hu01 | 激活素A(ACVA)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPA001Hu01 | 激活素A(ACVA)活性蛋白 | Cell?culture;?Activity?Assays. |
| UPAA001Hu01 | 激活素A(ACVA)多克隆抗體 | IHC |
| USEA001Hu | 激活素A(ACVA)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| UCEA001Hu | 激活素A(ACVA)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USCA001Hu | 激活素A(ACVA)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| ULMA001Hu | 激活素A(ACVA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| 13 | Secretory Products From Epicardial Adipose Tissue of Patients With Type 2 Diabetes Mellitus Induce Cardiomyocyte Dysfunction [Ahajournals: Source] |
| J. Pharmacogn | [Article: Hksobf_2015_V46N2_167] |
| United States Patent Application | Methods for Diagnosis and Treatment of Concussion or Brain Injury [2016:0103140] |
| BMC Cancer. | Activins and their related proteins in colon carcinogenesis: insights from early and advanced azoxymethane rat models of colon cancer. [pubmed:27835986] |
| Basic Clin Pharmacol Toxicol. | Magnolol Attenuates Concanavalin A-induced Hepatic Fibrosis, Inhibits CD4+ T Helper 17 (Th17) Cell Differentiation and Suppresses Hepatic Stellate Cell Activation: Blockade of Smad3/Smad4 Signalling. [pubmed:28032440] |
| Basic & Clinical Pharmacology & Toxicology | Magnolol Attenuates Concanavalin A-induced Hepatic Fibrosis, Inhibits CD4 + T Helper 17(Th17) Cell Differentiation and Suppresses Hepatic Stellate Cell Activation: Blockade of Smad3/Smad4 Signalling [doi:10.1111] |
| Journal of Immunology | MicroRNA-27b Modulates Inflammatory Response and Apoptosis during Mycobacterium tuberculosis Infection [Pubmed:29661829] |
| Journal of?Vascular?Surgery | Expression of platelet-derived growth factor B is upregulated in patients with thoracic aortic dissection [Pubmed:29685513] |
| Acta Biochimica et Biophysica Sinica | Toxic effects of arsenic trioxide on protoscoleces through ROS production, and Ca-ER stress-dependent apoptosis [10.1093:abbs] |
| Poultry?Science | The effect of raw and fermented rapeseed cake on the metabolic parameters, immune status, and intestinal morphology of turkeys [Pubmed:29917099] |
| Food Bioscience | Characterization of Phospholipids from Pacific Saury () Viscera and Their Neuroprotective Activity [10.1016:j.fbio.2018.06.002] |
| Current Analytical Chemistry | Single Wall Carbon Nanotube and Magnetic Bead Based Electrochemical Immunosensor for Sensitive Detection of Salivary Secretory Immunoglobulin A [10.2174:2211556006666170525161225] |
| Journal?of?Veterinary?Internal?Medicine | FRIDAY, NOVEMBER 3, 2017 11.30-12.0 BALLROOM AB [:] |
| Universal Journal of Pharmaceutical Research | SEROPREVALENCE OF ANTI-MANNOSE BINDING LECTIN AUTOANTIBODIES IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SANA'A CITY-YEMEN [10.22270:ujpr.v3i2.138] |
| Involvement of RBP4 in diabetic atherosclerosis and the role of vitamin D intervention [:] | |
| Clin Oral Investig.? | Gingival crevicular fluid levels of human beta-defensin-1 in type 2 diabetes mellitus and periodontitis [Pubmed:29713888] |
| Myocardial fibrosis in hypertrophic cardiomyopathy [:] | |
| TELLING TRANSVERSAL COMPETENCES… TO BE PROFESSIONALLY PROMOTED [:] | |
| Protein biomarker panels for detecting colorectal cancer and advanced adenoma [:] | |
| Endothelotropic activity of 4-hydroxy-3, 5-di-tret-butylcinnamic acid in the conditions of experimental cerebral ischemia [:] | |
| Silencing of the CSNK2β gene by siRNA inhibits invasiveness and growth of MDA-MB-231 cells [10.1101:311092] | |
| Duchenne Muscular Dystrophy | Flow Cytometry-Defined CD49d Expression in Circulating T-Lymphocytes Is a Biomarker for Disease Progression in Duchenne Muscular Dystrophy [Pubmed:29067667] |
| S | S [S] |
| P | P [P] |
| D | D [D] |
| h | h [h] |
| O | O [O] |
| M | M [M] |
| E | E [E] |
| I | I [I] |
| B | B [B] |
| T | T [T] |
| N | N [N] |
| [] | |
| [] | |
| L | L [L] |
| J | J [J] |
| Journal of Geriatric?Oncology | Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors [Pubmed: 30952517] |
| clinica chimica acta | The performances of serum activins and follistatin in the diagnosis of ectopic pregnancy: A prospective case-control study [Pubmed: 31647905] |
| hindawi | The Association between the Activin A Serum Level and Carotid Intima-Media Thickness in Chronic Kidney Disease Patients [] |
| Pathology & Oncology Research | Profiling Activins and Follistatin in Colorectal Cancer According to Clinical Stage, Tumour Sidedness and Smad4 Status [34867090] |
